Sphingosine kinase type 1 inhibitors and uses thereof

Patent metadata

Field	Value
Publication number	US-9974758-B2
Application number	US-201615181826-A
Country	US
Kind code	B2
Filing date	Jun 14, 2016
Priority date	Apr 29, 2008
Publication date	May 22, 2018
Grant date	May 22, 2018

Abstract

Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).

First claim

What is claimed is:

1. A method for treating a cancer in a mammal, the method comprising:
administering to a mammal in need of treatment for a cancer a sphingosine kinase Type I inhibitor having the formula

wherein
R 1 is OH;
R 2 is H or comprises a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing;
R 3 is NR 6 R 7 or N + R 6 R 7 R 8 ,
wherein R 6 , R 7 and R 8 independently comprise H, a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing;

R 4 is H or comprises OH, a halide, ═O, a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing;
R 5 is H or comprises OH, a halide, ═O, a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing; and
R 9 comprises a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing,

thereby inhibiting sphingosine kinase Type 1 in the mammal.

2. The method of claim 1 , wherein the mammal is a human.

3. The method of claim 2 , wherein the human has a cancerous tumor and said administration is performed in treatment thereof.

4. The method of claim 3 , wherein the cancerous tumor is a cancerous tumor of the central nervous system.

5. The method of claim 4 , wherein the cancerous tumor of the central nervous system is glioblastoma multiforme.

6. The method of claim 1 , wherein
R 2 is H, a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing;
R 3 is NR 6 R 7 or N + R 6 R 7 R 8 ,
wherein each of R 6 , R 7 and R 8 is independently H, a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing;

R 4 is H, OH, a halide, ═O, a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing;
R 5 is H or comprises OH, a halide, ═O, a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing; and
R 9 is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing.

7. The method of claim 6 , wherein R 9 is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, or a branched carbon chain comprising one or more heteroatoms.

8. The method of claim 1 , wherein
R 2 is H, a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring;
R 3 is NR 6 R 7 or N + R 6 R 7 R 8 ,
wherein each of R 6 , R 7 and R 8 is independently H, a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring;

R 4 is H, OH, a halide, ═O, a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring;
R 5 is H, OH, a halide, ═O, a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring; and
R 9 is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring.

9. A method for treating a cancer in a mammal, the method comprising:
administering to a mammal in need of treatment for a cancer a sphingosine kinase Type I inhibitor having the formula

10. The method of claim 9 , wherein the mammal is a human.

11. The method of claim 9 , wherein said administration comprises administering

to the mammal.

12. The method of claim 11 , wherein the mammal is a human.

Assignees

• Enzo Therapeutics Inc
• Univ Virginia Commonwealth

Inventors

• Spiegel Sarah
• Zipkin Robert Elliot
• Adams Jeffrey Kroll

Classifications

• C07C233/18

  having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton · CPC title

• C07D295/092

  with aromatic radicals attached to the chain · CPC title

• A61P11/06

  Antiasthmatics · CPC title

• C07D263/06

  with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms · CPC title

• C07C215/28

  and containing six-membered aromatic rings · CPC title